摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪 | 1320266-99-6

中文名称
3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪
中文别名
——
英文名称
3-(Tert-butyl)-8-chloroimidazo[1,5-a]pyrazine
英文别名
3-tert-butyl-8-chloroimidazo[1,5-a]pyrazine
3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪化学式
CAS
1320266-99-6
化学式
C10H12ClN3
mdl
——
分子量
209.678
InChiKey
RDQIAYLBZXDMOZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪N-碘代丁二酰亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 以70%的产率得到3-(叔丁基)-8-氯-1-碘咪唑并[1,5-a]吡嗪
    参考文献:
    名称:
    [EN] COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES
    [FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER LA TOXOPLASMOSE, LA CRYPTOSPORIDIOSE ET D'AUTRES MALADIES ASSOCIÉES AUX PROTOZOAIRES APICOMPLEXA
    摘要:
    本文描述了用于治疗由感染性真核寄生虫弓形虫(T. gondii)引起的弓形虫病和用于治疗由感染性真核寄生虫隐孢子虫(C. parvum)和人隐孢子虫(C. hominus)引起的隐孢子虫病的组合物和方法。具体而言,本公开涉及使用吡唑吡啶啉和/或咪唑[1,5-a]吡嗪类抑制剂来抑制T. gondii钙依赖蛋白激酶(TgCDPKs)或C. parvum和C. hominus钙依赖蛋白激酶(CpDPKS)的组合物和方法,其化学式为(I),其中变量X、Y、Z、L、R1和R3在此处定义。
    公开号:
    WO2011094628A1
  • 作为产物:
    参考文献:
    名称:
    [EN] COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES
    [FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER LA TOXOPLASMOSE, LA CRYPTOSPORIDIOSE ET D'AUTRES MALADIES ASSOCIÉES AUX PROTOZOAIRES APICOMPLEXA
    摘要:
    本文描述了用于治疗由感染性真核寄生虫弓形虫(T. gondii)引起的弓形虫病和用于治疗由感染性真核寄生虫隐孢子虫(C. parvum)和人隐孢子虫(C. hominus)引起的隐孢子虫病的组合物和方法。具体而言,本公开涉及使用吡唑吡啶啉和/或咪唑[1,5-a]吡嗪类抑制剂来抑制T. gondii钙依赖蛋白激酶(TgCDPKs)或C. parvum和C. hominus钙依赖蛋白激酶(CpDPKS)的组合物和方法,其化学式为(I),其中变量X、Y、Z、L、R1和R3在此处定义。
    公开号:
    WO2011094628A1
点击查看最新优质反应信息

文献信息

  • Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
    申请人:University of Washington through its Center for Commercialization
    公开号:US10544104B2
    公开(公告)日:2020-01-28
    Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.
    本发明描述了治疗由传染性真核寄生虫弓形虫(T. gondii)引起的弓形虫病和治疗由传染性真核寄生虫副隐孢子虫(C. parvum)和原隐孢子虫(C. hominus)引起的隐孢子虫病的组合物和方法。特别是,本公开涉及使用式中的吡唑嘧啶和/或咪唑并[1,5-a]吡嗪抑制剂抑制刚地隐孢子虫钙依赖性蛋白激酶(TgCDPKs)或副隐孢子虫和人隐孢子虫钙依赖性蛋白激酶(CpCDPKs)的组合物和方法、 其中变量 X、Y、Z、L、R1 和 R3 在本文中定义。
  • Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases
    申请人:VAN VOORHIS Wesley C.
    公开号:US20130018040A1
    公开(公告)日:2013-01-17
    Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii ( T. gondii ) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum ( C. parvum ) and Cryptosporidium hominus ( C. hominus ) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R 1 , and R 3 are defined herein.
  • Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases
    申请人:University of Washington through its Center for Commercialization
    公开号:US20180022709A1
    公开(公告)日:2018-01-25
    Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii ( T. gondii ) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum ( C. parvum ) and Cryptosporidium hominus ( C. hominus ) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R 1 , and R 3 are defined herein.
  • US9765037B2
    申请人:——
    公开号:US9765037B2
    公开(公告)日:2017-09-19
  • [EN] COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER LA TOXOPLASMOSE, LA CRYPTOSPORIDIOSE ET D'AUTRES MALADIES ASSOCIÉES AUX PROTOZOAIRES APICOMPLEXA
    申请人:UNIV WASHINGTON
    公开号:WO2011094628A1
    公开(公告)日:2011-08-04
    Compositions and methods for the treatment of toxoplasmosis-, caused by the infectious eukaryotic parasite Toxoplasma gondii (T, gondii) and for the treatment of ciyptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C parvuai) and Cnγtosporidium homimus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpDPKS) using pyrazolopyriinidine and/or imidazo[l,5-a]pyraziαe inhibitors, of the formula.(I), wherein the variables X. Y, Z, L. R1. and R3 are defined herein.
    本文描述了用于治疗由感染性真核寄生虫弓形虫(T. gondii)引起的弓形虫病和用于治疗由感染性真核寄生虫隐孢子虫(C. parvum)和人隐孢子虫(C. hominus)引起的隐孢子虫病的组合物和方法。具体而言,本公开涉及使用吡唑吡啶啉和/或咪唑[1,5-a]吡嗪类抑制剂来抑制T. gondii钙依赖蛋白激酶(TgCDPKs)或C. parvum和C. hominus钙依赖蛋白激酶(CpDPKS)的组合物和方法,其化学式为(I),其中变量X、Y、Z、L、R1和R3在此处定义。
查看更多

同类化合物

顺式-3-(8-氨基-1-溴咪唑并[1,5-a]吡嗪-3-基)-1-甲基环丁醇 咪唑并[1,5-a]吡嗪-8-胺 咪唑并[1,5-a]吡嗪-8(7H)-硫酮 N-(2,6-二甲基苯基)-5-(4-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 N-(2,6-二甲基苯基)-5-(3-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 8-氯咪唑并[1,5-a]吡嗪 8-氯咪唑并[1,5-A]吡嗪-1-甲酸乙酯 8-氯-3-环丁基-1-碘-咪唑并[1,5-a]吡嗪 8-氯-3-异丙基咪唑并[1,5-A]吡嗪 5H,10H-二咪唑并[1,5-a:1, 5-d] 吡嗪-5,10-二酮 5-溴-7-(4-甲氧基苄基)咪唑并[1,5-a]吡嗪-8-(7H)-酮 5-(4-甲氧基苯基)-7H-咪唑并[1,5-a]吡嗪-8-酮 5,10-二氧代-5H,10H-二咪唑并[1,5-a:1',5'-d]吡嗪-1,6-二甲酸 3-甲基咪唑并[1,5-a]吡嗪-8(7H)-硫酮 3-甲基咪唑并[1,5-A]吡嗪 3-环己基咪唑并[1,5-a]吡嗪 3-环丁基-1-碘-咪唑并[1,5-a]吡嗪-8-胺 3-(甲硫基)-1-硝基-咪唑并[1,5-a]吡嗪 3-(甲氧基甲基)-咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯-1-碘咪唑并[1,5-a]吡嗪 3-(三氟甲基)咪唑并[1,5-a]吡嗪 3-(8-BROMO-1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 3-(1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 1-碘-3-叔丁基咪唑并[1,5-a]吡嗪-8-胺 1-溴-3-甲基-咪唑并[1,5-a]吡嗪 1-溴-3-(四氢-2H-吡喃-4-基)咪唑并[1,5-a]吡嗪-8-胺 (S)-1-bromo-8-methyl-3-(pyrrolidin-3-yl)imidazo[1,5-a]pyrazine hydrochloride tert-butyl (4-(1-bromo-3-isopropylimidazo[1,5-a]pyrazin-5-yl)cyclohex-3-en-1-yl)(methyl)carbamate 8-chloro-5-phenylimidazo[1,5-a]pyrazine 3-(6-(1,4-diazepan-1-yl)pyridin-2-yl)-6-(6-methylpyrazin-2-yl)imidazo[1,5-a]pyrazine N-(2,6-dimethylphenyl)-5-{3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}imidazo[1,5-a]pyrazin-8-amine 3-bromo-8-chloroimidazo[1,5-a]pyrazine N3-(2,4-Dichloro-phenyl)-N8,N8-diethyl-1-methyl-imidazo[1,5-a]pyrazine-3,8-diamine 7-(3-fluorobenzyl)-6-methyl-3(S)-(3-methyltetrahydrofuran-3-yl)imidazo[1,5-a]pyrazin-8(7H)-one E-1-(6,7-dimethyl-8-oxo-7,8-dihydroimidazo[1,5-a]pyrazin-1-yl)-2-ethyl-3-phenylisothiourea 7-(3-chloro-4-methoxybenzyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one 8-chloro-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazine 3-cyclobutyl-1-(phenylethynyl)imidazo[1,5-a]pyrazin-8-amine ethyl 1-bromoimidazo[1,5-a]pyrazine-3-carboxylate Imidazo[1,5-a]pyrazine-3-carboxylic acid,1-(4-morpholinyl)-,ethyl ester Imidazo[1,5-a]pyrazine-1-methanol,8-chloro- methyl 3-methylimidazo[1,5-a]pyrazine-1-carboxylate Imidazo[1,5-a]pyrazine-1-methanol,8-chloro-6-methyl- Ethyl 8-Hydroxyimidazo[1,5-a]pyrazine-1-carboxylate Imidazo[1,5-a]pyrazine,8-chloro-6-phenyl- (1S,6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyltetrahydro-1H-oxazolo[3,4-a]pyridin-3(5H)-one (1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)methanol 3-((1H-imidazol-1-yl)methyl)-1-bromo-8-methylimidazo[1,5-a]pyrazine 8-methyl-3-(piperidin-4-yl)imidazo[1,5-a]pyrazine